Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

Introduction

• Org Study ID: 2024-0919
• NCT ID: NCT06601296
• Lead Sponsor Name: University of Texas Southwestern Medical Center
• Status: RECRUITING

Conditions

• Clear Cell Renal Cell Carcinoma

Brief Summary

To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).

Eligibility Criteria

Inclusion Criteria:

* Patients must have metastatic ccRCC.
* Patients must have oligoprogression defined as progression in ≤5 lesions.
* All oligoprogression lesions must be suitable for radiation.
* Patients must have at least one site of disease that can be safely injected with IMSA101.
* Karnofsky Performance Status (KPS) of at least 50%.
* Age ≥ 18 years.
* Patients must have adequate organ and marrow function within 14 days prior to study entry.
* All IMDC risk categories are allowed.

Exclusion Criteria:

* Patients with progressive ultracentral/central chest lesions will be excluded